Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. RECEIVES APPROVAL FOR THE EXTENSION OF ANNUAL GENERAL AND SPECIAL MEETING TO SEEK APPROVAL OF ASSET ACQUISITIONS AND PROPOSED FINANCING

Further to Helix BioPharma Corp.'s news release dated Feb. 21, 2025, the annual general and special meeting for the year ended July 31, 2024, has been extended to March 26, 2025, to provide additional time to seek shareholder approval with respect to its proposed asset acquisitions from Laevoroc Immunology AG and Laevoroc Chemotherapy AG (the asset acquisitions), as well as a proposed financing utilizing a draw-down subscription facility structure.

The company applied to the Ontario Superior Court of Justice for an order under Section 133(3) of the Canada Business Corporations Act permitting it to hold the meeting by March 26, 2025. The application was approved on Wednesday, Feb. 26, 2025.

The notice of meeting, management information circular, financial statements request form, form of proxy and voting instruction form (the meeting materials) have been mailed to shareholders and were posted on the company's profile on SEDAR+ on Feb. 24, 2025.

Shareholders of record as of Jan. 31, 2025, are entitled to vote their shares of the company at the meeting. The company encourages its shareholders to vote in advance of the meeting using the instructions on the voting instruction form or the form of proxy that will be mailed to them with the meeting materials. Shareholders are reminded that proxies must be received by 10 a.m. ET on March 24, 2025.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company shaping a near future where today's hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The company innovates from strength to tackle cancer's biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bio- conjugates that score with precision against prevalent CEACAM6-expressing solid tumours. Its lead candidate, Tumour Defence Breaker L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumours, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today's front-running anti-cancer therapies. L-DOS47 has completed phase Ib studies in non-small cell lung cancer (NSCLC), with novel strategically designed bi-specific ADCs targeting CEACAM6 in discovery.

Helix is listed on the Toronto Stock Exchange under the symbol HBP, on OTC Pink under the symbol HBPCD and on FWB under the symbol HBP0.

We seek Safe Harbor.